Defining therapy goals for major molecular remission in chronic myeloid leukemia

• Verfasst von: Saußele, Susanne [VerfasserIn]
• Verfasst von: Hehlmann, Rüdiger [VerfasserIn]
• Verfasst von: Fabarius, Alice [VerfasserIn]
• Verfasst von: Rinaldetti, Sébastien [VerfasserIn]
• Verfasst von: Kohlbrenner, Katharina [VerfasserIn]
• Verfasst von: Hofmann, Wolf-Karsten [VerfasserIn]
• Verfasst von: Müller, Martin Christian [VerfasserIn]
• Titel: Defining therapy goals for major molecular remission in chronic myeloid leukemia
• Titelzusatz: results of the randomized CML Study IV
• Verf.angabe: Susanne Saussele, Rüdiger Hehlmann, Alice Fabarius, Sabine Jeromin, Ulrike Proetel, Sebastien Rinaldetti, Katharina Kohlbrenner, Hermann Einsele, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Elisabeth Oppliger Leibundgut, Dominik Heim, Stefan W. Krause, Wolf-Karsten Hofmann, Joerg Hasford, Markus Pfirrmann, Martin C. Müller, Andreas Hochhaus, Michael Lauseker
• E-Jahr: 2018
• Jahr: 26 February 2018
• Umfang: 7 S.
• Fussnoten: Gesehen am 29.09.2020
• Titel Quelle: Enthalten in: Leukemia
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 2018
• Band/Heft Quelle: 32(2018), 5, Seite 1222-1228
• ISSN Quelle: 1476-5551
• DOI: doi:10.1038/s41375-018-0055-7
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1733945903

Abstract

Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecular remission status Hazard ratios (HR) were estimated for patients registered to CML study IV who were divided in a learning and a validation sample. The minimum HR for MMR was found at 2.5 years with 0.28 (compared to patients without remission). In the validation sample, a significant advantage for progression-free survival (PFS) for patients in MMR could be detected (p-value 0.007). The optimal time to predict PFS in patients with MMR could be validated in an independent sample at 2.5 years. With our model we provide a suggestion when to define lack of MMR as therapy failure and thus treatment change should be considered. The optimal response time for 1% BCR-ABL at about 12-15 months was confirmed and for deep molecular remission no specific time point was detected. Nevertheless, it was demonstrated that the earlier the MMR is achieved the higher is the chance to attain deep molecular response later.